Key result
Prothrombin levels link to bleeding and recurrent thrombosis risks during ambulatory coumarin-type anticoagulation.
Observational
Answers are grounded in this paper and cite their sources.
THE increasing enthusiasm for treating thromboembolic diseases with prothrombin-reducing drugs for long periods in ambulatory patients has emphasized the lack of clear definition of the therapeutic range of anticoagulation. These are now more often older patients with vascular disease who are difficult to manage, sometimes follow instructions poorly and are more prone to bleeding complications than the younger patients, who are usually treated for recurrent phlebitis, pulmonary embolism or peripheral embolism from heart disease.Control of therapy has traditionally been carried on with the "prothrombin-time" test of Quick.∥ This test has proved remarkably satisfactory considering the great variation of opinion . . .
No takes yet. Share an insight, caveat, or question.
Sise et al. (1958) conducted an observational in Thromboembolic diseases. Coumarin-type anticoagulants (prothrombin-reducing drugs) was evaluated on Hemorrhage and thrombosis in relation to prothrombin levels. Coumarin-type anticoagulant therapy in ambulatory thromboembolic patients was evaluated regarding the relationship of prothrombin levels to hemorrhage and thrombosis (no numeric results in excerpt).
Synapse has enriched 10 related papers. Consider them for comparative context: